Hypoxia is a state of very low oxygen levels, p(O 2 ) < 5 mmHg, encountered in some areas of solid tumors, which can lead to the development of a more malignant and resistant cellular phenotype poorly responsive to both radiotherapy and chemotherapy. Targeting hypoxic regions in tumors has been proposed as a possible novel therapeutic approach in oncology.
The first series of projects from the group of Professor Thomas Poulsen at Aarhus University (Denmark) has been focused on bioactive compounds, notably those with anticancer activities. However, the group is also interested in other types of biological activity. "All projects in our lab stem from an interest in uniting chemistry and biology with the overall aim -or perhaps vision is a better word -of contributing to an increased understanding of human disease and the development of new types of treatments," said Professor Poulsen.
The BE-43547 project sprang from studies that were initially focused on the natural depsipeptide rakicidin A (Figure 1a). Professor Poulsen explained: "This compound was pre viously reported to selectively kill both hypoxic cancer cells and stem-like leukaemia cells, which I found fascinating. Hypoxia designates a state of low oxygen levels in cells and it turns out that this is an important clinical parameter, as strong correlations exist between tumor hypoxia, disease progression, metastasis, and mortality (Science 2016, 352, 175) ."
Rakicidin A contains a trademark chemical functionality: the 4-amido-2,4-pentadienoate group (APD group, Figure 1a blue). This structural motif is only known in three different macrocyclic depsipeptides: rakicidin, vinylamycin/microtermolide A (not shown), and BE-43547 molecules ( Figure 1a) . "All the APD-containing natural products also contain a lipid chain of varying length and branching," remarked Professor Poulsen. He continued: "We have therefore classified these molecules as APD-CLDs (amidopentadienoate-containing cyclolipodepsipeptides)." "Rakicidin A was our first APD-CLD synthesis target," said Professor Poulsen, "a choice that was dictated by the fact that this compound had the most detailed bioactivity profile,
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although the related BE-43547 molecules were also reported to be potent cytotoxins (Japanese Patent JP10147594 A 19980602, 1998). We synthesized rakicidin A and confirmed its biological activity (Angew. Chem. Int. Ed. 2016 , 55, 1030 , a challenge that the Yue Chen lab managed to overcome while we were still working on our total synthesis (J. Am. Chem. Soc. 2014, 136, 15787) ." He went on, explaining: "We started our work on the BE-43547 class while we were still working on the rakicidin A synthesis and aimed our route for the A 1 -congener, as this was reported to be marginally more potent than the other family members (Japanese Patent 10147594 A 19980602, 1998), but in reality this choice was as much based on the 'A 1 '-label. This rather arbitrary (and it would appear harmless) choice actually turned out to be quite troublesome, as we eventually had to re-isolate the natural product and the A 1 /A 2 -congeners were by far the less abundant family members."
The group designed a retrosynthetic strategy that would allow access to all possible stereoisomers (Figure 1b ), since no stereochemical information was provided in the isolation patent. "Based on experience from a model system that we developed early on (Chem. Commun. 2011, 47, 12837), we predicted that the APD unit would be unstable and we therefore decided to pursue a formal dehydration of alcohol 2 to form the exocyclic double bond in the final transformation," said Professor Poulsen. He continued: "According to our plan, macrocyclization should take place at the double bond via an intramolecular Horner-Wadsworth-Emmons (HWE) olefination, and the cyclization precursor would be constructed via a series of amide and ester couplings from fragment 3 (Fi gure 1b)." Thus, the first main challenge for the group was to con struct compound 3, with control of all three stereogenic centers. The authors hypothesized that the two adjacent stereocenters on carbon 21 and 19 could be controlled with full flexibility using an asymmetric Kobayashi vinylogous aldol reaction (J. Am. Chem. Soc. 2004, 126, 13604; Org. Lett. 2012, 14, 5298) .
"This strategy was very appealing, as the precedence for obtaining stereocontrol was convincing and at the same time it would provide a double bond functionality that we could subsequently use to oxidatively install the α-ketol system. Here, we hoped that an asymmetric dihydroxyl ation reaction could override eventual substrate bias and achieve full control of the stereocenter at carbon 15 -an idea which ultimately stayed in the 'hope' category," said Professor Poulsen.
The forward synthesis started with a three-step synthesis of aldehyde 4 and a two-step synthesis of TBS enolate 5 (Scheme 1). The two fragments were coupled in a vinylogous aldol reaction promoted by TiCl 4 . "As expected, the relative stereochemistry of the two new stereocenters could be controlled by the stoichiometry of TiCl 4 ," said Professor Poulsen. An excess (4 equiv) yielded the syn-isomer in a dr > 40:1 (not shown), while one equivalent of TiCl 4 yielded the anti-isomer (6-anti) in dr > 20:1 (Scheme 1).
Professor Poulsen added: "The origin of this high diastereomeric control is not known in detail, but the usefulness is unquestionable. The aldol reaction along with the Evans auxiliary gave us complete control over the stereochemistry of carbons 21 and 19 with maximal convergence." 10-anti (Scheme 1). The ester coupling was promoted via an in situ acid fluoride formation from the carboxylic acid 8, a strategy that proved superior to more common esterification strategies, for example Steglich conditions. "As already mentioned, the dihydroxylation proved to be a major challenge, and we had no success with catalytic Sharpless-type reactions along with non-asymmetric dihydro xylations using RuCl 3 , KMnO 4 , or OsO 4 ," said Professor Poulsen. "Finally, we had to resort to superstoichiometric OsO 4 in pyridine, which yielded the dihydroxylated product (dr = 1.3:1), which could be advanced to compound 10-anti as the diastereomeric mixture. Working with a mixture proved a significant challenge when analyzing the products, but ultimately the low selectivity in the dihydroxylation was an advantage, since we needed to access both stereoisomers."
In the end-game sequence, alcohol 10-anti was oxidized to the aldehyde and cyclized via a Horner-Wadsworth-Emmons reaction using the Helquist conditions (Scheme 1). Professor Poulsen revealed that alternatives such as using strong base or Roush-Masamune conditions (DBU, LiCl) proved unsuitable for this transformation. "After cyclization, the two diastereomers could be separated into 11-anti P1 and P2. TBS deprotection, mesylation and then elimination could yield the final products 1-A 1 -anti P2 and P1. The aldol product 6-syn was advanced using the same sequence of transformations to yield the two products 1-A 1 -syn P2 and P1," he added.
PhD student Nikolaj Villadsen, the first author of the paper, took up the story: "I soon found that the 1-A 1 compounds demanded caution during purification. The product seemed unstable when concentrated from solution and, based on an insoluble solid we obtained in several experiments, we suspect that it can polymerize. As has been observed with other APD-CLD members, these compounds can instead be concentrated without degradation by lyophilization from a frozen mixture of DMSO or water-MeCN."
In possession of all four diastereomers of the natural product, direct comparison with the reported NMR data should now reveal which diastereomer was the natural one. The stereochemistry of carbon 15 was to be elucidated, once it was clear which compound to focus on. Nikolaj Villadsen recalled: "To our despair, we finally concluded that none of the four synthesized compounds had a satisfying overlap with the NMR data from the patent. Only the tabulated NMR data was given, no spectra were included. We recorded NMR data in deuterated benzene, chloroform, pyridine, water, acetone, and acetonitrile to see if we could get a match, but without success. Those were not good days." Professor Poulsen explained: "Attempted contact with any of the patent authors was unsuccessful, leaving us at what seemed to be a pretty painful dead end. We first speculated that the assigned structure was incorrect, more specifically we thought that the N-methyl group was misplaced. To advance the project, we clearly needed access to the natural product itself, but no known BE-43547 producing bacteria were available."
Professor Thomas Tørring, co-senior author on the paper, added: "The only annotated biosynthetic gene cluster of an APD-CLD family member that could be found was for rakicidin D. When searching for a similar cluster we could only find a few that were clearly also encoding rakicidin-like molecules, but curiously the ones we did find had a rearrangement in one of the polyketide modules -the dehydratase and ketoreduct ase were swapped. This appeared to be the module responsible for constructing the APD portion of the rakicidins; therefore, we decided to use this as a BLAST query. This gave roughly twenty homologues and the corresponding biosynthetic gene clusters appeared to cover all the known APD-CLDs -and most importantly two gene clusters that looked to encode the BE-43547 molecules (Figure 2a) . Interestingly, this search also revealed a series of hitherto unknown APD-containing natural products." Professor Tørring continued: "We obtained the two bacterial strains Salinispora arenicola CNR107 and Micromonospora sp. RV43, and hoped that laboratory production of the compounds was feasible. We were very encouraged when we conducted preliminary LC-MS/MS analysis of bacterial extracts and identified compounds with a fragmentation pattern that was virtually identical to the synthesized 1-A 1 -anti P2 (Figure 2b ). We now know that both rakicidin A and BE-43547 afford a fragment ion with the mass 96.045 Da, which we believe can be attributed to the APD unit and therefore is likely to be found in all APD-CLD family members."
The match in fragmentation pattern between the synthesized and natural product suggested that the assigned connectivity was correct, i.e., that the N-methyl group was correctly placed in the structure, and that the team therefore had to isolate the natural product to acquire their own NMR data. "We cultured bacteria on large scale and performed a series of ex traction and purification steps to finally afford BE-43547A 1 and A 2 ," said Nikolaj Villadsen. He continued: "This was not a trivial procedure, but very much worth the effort when final NMR comparison between the isolated natural product and the four synthetic compounds showed 1-A 1 -anti P2 had perfect overlap (Figure 2c ). Ironically, this compound was synthesized all the way back in the spring of 2015 as the second isomer that I prepared." Professor Poulsen took up the story again: "CD spectroscopy showed that the synthesized compound was the enantiomer of the natural product. NOE experiments along with structure conformation optimization via DFT calculations helped us determine the stereochemistry of 1-A 1 -anti P2 as (R,R,R)-ent-1-A 1 , and therefore the natural product has (S,S,S)-configuration. Evaluation of cytotoxicity under normal and low oxygen levels (normoxia and hypoxia) of the isolated and synthesized products showed that BE-43547A 1 possesses the same hypoxia-selective phenotype as rakicidin A and is even more selective (Figure 3) . A rather curious observation that we also made was the near equipotent biological activity of the enantiomeric material." "BE-43547A 2 is the most hypoxia-selective APD-CLD family member yet known, which I think is a really exciting discovery," said Professor Poulsen. "Together with clinical experts on tumor hypoxia, we are conducting preliminary investigations of their in vivo potential. However, the structure needs to be simplified -which we are working hard on realizingwhile still maintaining these high levels of hypoxia selectivity in order to support a more extensive pre-clinical program. Our current biological focus on this project is to unravel the mechanism of action that underlies the potent toxicity of these compounds, studies that have so far taken us in several 
